<SEC-DOCUMENT>0001213900-21-065211.txt : 20211214
<SEC-HEADER>0001213900-21-065211.hdr.sgml : 20211214
<ACCEPTANCE-DATETIME>20211214164837
ACCESSION NUMBER:		0001213900-21-065211
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211214
DATE AS OF CHANGE:		20211214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clene Inc.
		CENTRAL INDEX KEY:			0001822791
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258098
		FILM NUMBER:		211491603

	BUSINESS ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121
		BUSINESS PHONE:		801-676-9695

	MAIL ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chelsea Worldwide Inc.
		DATE OF NAME CHANGE:	20200827
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea152327-424b3_cleneinc.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROSPECTUS
    SUPPLEMENT NO. 8</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(To
    Prospectus Dated April 19, 2021)</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
    No. 333-253173</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    Pursuant to Rule 424(b)(3)</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROSPECTUS
    SUPPLEMENT NO. 4</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(To
    Prospectus Dated August 2, 2021)</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
    No. 333-258098</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Up
to 29,894,305 Shares of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Prospectus Supplement (the &ldquo;Supplement&rdquo;) is being filed by Clene Inc. (the &ldquo;Company&rdquo;) to update and supplement
the Company&rsquo;s (i) prospectus, dated April 19, 2021 (&ldquo;Prospectus #1&rdquo;), as supplemented by Prospectus Supplement No.
1, filed on May 12, 2021, Prospectus Supplement No. 2, filed on May 24, 2021, Prospectus Supplement No. 3, filed on June 10, 2021, Prospectus
Supplement No. 4, filed on July 16, 2021, Prospectus Supplement No. 5, filed on August 11, 2021, Prospectus Supplement No. 6, filed on
September 29, 2021, and Prospectus Supplement No. 7, filed on November 10, 2021, which form a part of the Company&rsquo;s Registration
Statement on Form S-1 (Registration No. 333-253173) relating to the offering of up to 4,541,481 shares of the Company&rsquo;s common
stock (&ldquo;Common Stock&rdquo;) by the Company and the resale of up to 23,251,553 shares of Common Stock by the selling shareholders
identified in the prospectus; and (ii) prospectus, dated August 2, 2021 (&ldquo;Prospectus #2&rdquo; and together with Prospectus #1,
the &ldquo;Prospectuses&rdquo;), as supplemented by Prospectus Supplement No. 1, filed on August 11, 2021, Prospectus Supplement No.
2, filed on September 29, 2021, and Prospectus Supplement No. 3, filed on November 10, 2021, which form a part of the Company&rsquo;s
Registration Statement on Form S-1 (Registration No. 333-258098) relating to the offering of up to 1,140,731 shares of Common Stock by
the Company and the resale of up to 960,540 shares of Common Stock by the selling shareholders identified in the prospectus. This Supplement
should be read in conjunction with the Prospectuses, and this Supplement is not complete without, and may not be delivered or utilized
except in connection with, the Prospectuses, including any amendments or supplements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
there is any inconsistency between the information in the Prospectuses and this Supplement, you should rely on the information in this
Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Supplement is being filed to update the information in the Prospectuses with the information contained in the Company&rsquo;s Current
Report on Form 8-K (the &ldquo;Current Report&rdquo;), filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
on December 14, 2021. A copy of the Current Report is included below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our securities involves risks that are described in the &ldquo;<I>Risk Factors</I>&rdquo; section beginning on page&nbsp;11 of Prospectus
#1 and page 8 of Prospectus #2. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Neither
the SEC nor any state securities commission has approved or disapproved of these securities or determined if this Supplement (or the
Prospectuses including any supplements or amendments thereto) is truthful or complete. Any representation to the contrary is a criminal
offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
date of this Prospectus Supplement is December 14, 2021.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM <FONT ID="xdx_906_edei--DocumentType_c20211213__20211213_zXmOqp9kX41h">8-K</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 OR 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):
<FONT ID="xdx_90E_edei--DocumentPeriodEndDate_c20211213__20211213_zKIEVsEdgmF4">December 13, 2021</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="xdx_904_edei--EntityRegistrantName_c20211213__20211213_zyoWz4NKuhfd">Clene Inc.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT ID="xdx_906_edei--EntityIncorporationStateCountryCode_c20211213__20211213_zN1jLe59HyH">Delaware</FONT></B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT ID="xdx_905_edei--EntityFileNumber_c20211213__20211213_zgb8cwBtaz66">001-39834</FONT></B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT ID="xdx_90B_edei--EntityTaxIdentificationNumber_c20211213__20211213_znyWIKwFr97d">85-2828339</FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(State or other jurisdiction</B></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(IRS Employer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>of incorporation)</B></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Identification No.)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT ID="xdx_900_edei--EntityAddressAddressLine1_c20211213__20211213_zXbnfLuDsyzk">6550 South Millrock Drive</FONT>, <FONT ID="xdx_90D_edei--EntityAddressAddressLine2_c20211213__20211213_zzjN9amIOvDl">Suite G50</FONT><BR>
<FONT ID="xdx_901_edei--EntityAddressCityOrTown_c20211213__20211213_zgbWngXpTYb2">Salt Lake City</FONT>, <FONT ID="xdx_909_edei--EntityAddressStateOrProvince_c20211213__20211213_zDQZYqBlIQ6h">Utah</FONT></B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT ID="xdx_908_edei--EntityAddressPostalZipCode_c20211213__20211213_z0XvfW79GN0a">84121</FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Zip Code)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&#8217;s telephone number, including
area code: <FONT ID="xdx_909_edei--CityAreaCode_c20211213__20211213_zYO9zzI2xj4c">(801)</FONT> <FONT ID="xdx_90D_edei--LocalPhoneNumber_c20211213__20211213_zclOETjOG9Qb">676-9695</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed since
last report.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_906_edei--WrittenCommunications_c20211213__20211213_znI3SCmTFBNa">&#9744;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_909_edei--SolicitingMaterial_c20211213__20211213_zGEbWcQoBV77">&#9744;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_907_edei--PreCommencementTenderOffer_c20211213__20211213_z2GN1fe7hvNf">&#9744;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20211213__20211213_zbmqfT7uknUf">&#9744;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title of each class</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name of each exchange on<BR>
which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_903_edei--Security12bTitle_c20211213__20211213__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValueUs0.0001PerShareMember_zkqqEve9ckbl">Common Stock, par value US$0.0001 per share</FONT></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_90D_edei--TradingSymbol_c20211213__20211213__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValueUs0.0001PerShareMember_zYrQGeT66nKa">CLNN</FONT></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The <FONT ID="xdx_90A_edei--SecurityExchangeName_c20211213__20211213__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValueUs0.0001PerShareMember_zZz3AlKZDr8d">Nasdaq</FONT> Capital Market</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_90B_edei--Security12bTitle_c20211213__20211213__us-gaap--StatementClassOfStockAxis__custom--WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor11.50PerShareMember_zsmKl9rdhXrb">Warrants, to acquire one-half of one share of Common Stock for $11.50 per share</FONT></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT ID="xdx_908_edei--TradingSymbol_c20211213__20211213__us-gaap--StatementClassOfStockAxis__custom--WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor11.50PerShareMember_zrWeczhqT4E1">CLNNW</FONT></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The <FONT ID="xdx_90B_edei--SecurityExchangeName_c20211213__20211213__us-gaap--StatementClassOfStockAxis__custom--WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor11.50PerShareMember_z4bgaPfjQzLl">Nasdaq</FONT> Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT ID="xdx_90F_edei--EntityEmergingGrowthCompany_c20211213__20211213_zfzImFKfDRf5">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <FONT ID="xdx_90B_edei--EntityExTransitionPeriod_c20211213__20211213_zIKI0Ixrkc9f">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 13, 2021, Clene Inc. (the &#8220;Company&#8221;)
issued a press release announcing its wholly owned subsidiary, Clene Nanomedicine, Inc., received a $1.0 million grant award from the
Maryland Department of Housing and Community Development to support its manufacturing facility improvement project in Elkton, Maryland.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release dated December 13, 2021 announcing Clene Nanomedicine&#8217;s facility improvement project receives $1 million grant award from the Maryland Department of Housing and Community Development.</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">104</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (formatted as Inline XBRL).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Clene Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD COLSPAN="2">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: December 14, 2021</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><A NAME="a_001"></A><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Clene Nanomedicine&rsquo;s Facility Improvement
Project Receives<BR>
$1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>Clene Nanomedicine&rsquo;s Maryland facility is among the projects and activities awarded funding</I></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>The manufacturing expansion is in preparation for anticipated commercialization</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SALT LAKE CITY, Dec. 13, 2021 -- Clene Inc. (NASDAQ: CLNN) along with
its subsidiaries &ldquo;Clene&rdquo; and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company
focused on revolutionizing the treatment of neurodegenerative disease, announced a $1 million grant award from the Maryland Department
of Housing and Community Development (DHCD) to further support the redevelopment of the Clene manufacturing facility in Elkton, MD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The legacy site is being redeveloped for pharmaceutical product development
to increase Clene&rsquo;s manufacturing capacity and support anticipated product commercialization for amyotrophic lateral sclerosis (ALS)
with Clene&rsquo;s lead asset, CNM-Au8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;Clene is committed to supporting the infrastructure growth of
the Maryland community, and we are grateful for this recognition by the State of Maryland and the assistance of the Town of Elkton,&rdquo;
said Mark Mortenson, Founder &amp; Chief Scientific Officer of Clene Nanomedicine. &ldquo;Maryland&rsquo;s community of innovators and
state-of-the-art facilities will enable the accelerated development of Clene&rsquo;s neuroprotective therapeutic. We look forward to expanding
our partnership with the State and the Town of Elkton.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The project aims to attract additional work force and investment, and
continued discussions are presently underway with the State of Maryland and the Town of Elkton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Visit here for the full release and here for a the full list of awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Clene</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Clene is a clinical-stage biopharmaceutical company focused on revolutionizing
the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure, an underlying cause
of many neurological diseases. Our lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular
energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair
and improve neuroprotection. CNM-Au8 is currently being evaluated in a Phase 3 registration trial in amyotrophic lateral sclerosis (ALS)
and a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). Clene has
also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based
in Salt Lake City, Utah, with R&amp;D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow
us on Twitter, LinkedIn and Facebook.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release contains &ldquo;forward-looking statements&rdquo;
which are intended to be covered by the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995.
Clene&rsquo;s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words such as &ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;project,&rdquo;
&ldquo;budget,&rdquo; &ldquo;forecast,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;might&rdquo;
and &ldquo;continues,&rdquo; and similar expressions are intended to identify such forward-looking statements. These forward-looking statements
involve significant known and unknown risks and uncertainties, many of which are beyond Clene&rsquo;s control and could cause actual results
to differ materially and adversely from expected results. Factors that may cause such differences include Clene&rsquo;s ability to demonstrate
the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development
or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing
approval; Clene&rsquo;s ability to achieve commercial success for its marketed products and drug candidates, if approved; Clene&rsquo;s
ability to obtain and maintain protection of intellectual property for its technology and drugs; Clene&rsquo;s reliance on third parties
to conduct drug development, manufacturing and other services; Clene&rsquo;s limited operating history and its ability to obtain additional
funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19
pandemic on Clene&rsquo;s clinical development, commercial and other operations, as well as those risks more fully discussed in the section
entitled &ldquo;Risk Factors&rdquo; in Clene&rsquo;s Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties,
and other important factors in Clene&rsquo;s subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no
obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or
any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in
this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall
not be deemed to be, part of or incorporated into this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Media Contact</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maggie Beller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maggie.Beller@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1-646-942-5631</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Investor Contact</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director, Westwicke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">clene@westwicke.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1-443-213-0506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !C :4# 2(  A$! Q$!_\0
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ME5IXJFJE.I"K3E%-3A*,HN+2::<925FFNNH^BBD) ZD#ZG%4:BT444 %%%%
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M.$G&I'>46KR/ZXX5XSR?BK"1Q66U8J5ESTI2BIPDTKIIM2:3;5[6T[Z'7@8
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M'4<WEI\/M(TN'7OB2VGY5OLNK/,Z^%_ ETZ,3&F/&%N"I6Y\(6Y.:_6+3O\
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M9O25E3C-WT2T/YKR[Q7\2N(\7+"Y+2C*-[<T<F<HIW=DZEW%/9-MKT/Z ?\
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MSU/Y/OV]9?-_;;_:WFG/3]I#X[CT'_)3M?[#VYX'/:OE"OK;]O\ B\G]N/\
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MU[=\#_ZY-?"O[87[ 7[-/[;>AZ/I_P :_!MS=ZMX>._P[XS\-71\,^--%M&
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MBE^[GLDE9;W=C_+J_:P_Y.?_ &D/^R[_ !D_]337J_T+?^"97_)@'[(6.O\
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MZ2ELZTG17O.]W*HX66MV^BUW1_-W6A9:;?:E=6]CI-C<ZEJ%U>?8K.SM+/\
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MSV\\44]O.K6]Q%,,J5P05(^8,2&^[CD$$$'K_+U_P4-_X( :;\0M5\0?%O\
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M/^TG"FHJSD^6*N[6NS] ?^#=_P"-?[3GQ5\(?''1_BSXC\;>/OA/X:O?"[^
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M*7PHT\A/$UAXDB\TZYXS\%:+@1^(I?%%O"LL_AF,GQ8WC%TN('DMIX9/!_\
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MU7^TZ;S'S7W@KX$^&WC3:5)S'X]^($;0NV3C8WPD3IRPQS_0%^S/_P $@_\
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M_P NW3[M@HHHI@%%%% !1110!AZII.E:S8S6.IV&G:C8W"@7%OJ5I'?V5RI
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M2OZ\T60^1%_SSC_[X_\ KT>1%_SSC_[X_P#KU-13YI?S2^]_YB]C1_Y]4O\
MP73_ /D!@C0?P)[80#_&GT45+;>[;]6W^;92C&/PQBK[VC%7];)";1Z#\J"!
MC&!^(R/RI:*!V5N6RMVLK?=M^ S8O]U/^^!_C2>6G]R/_OV/\:DHIW?=_>_\
MR?9T_P#GW#_P"'_R)'Y2'JD9_P"V8_QH$:CHL8^B ?UJ2BB[[O[W_F'LZ?\
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
